Troxevasin capsules 300mg, No. 100

Chronic venous insufficiency, postphlebitic syndrome, trophic disorders in varicose veins and trophic ulcers. As an adjunct treatment after vein sclerotherapy and removal of varicose veins. Hemorrhoids (pain, exudation, itching and bleeding).

Venous insufficiency and hemorrhoids during pregnancy, starting from the second trimester.

As an adjunct treatment for retinopathy in patients with diabetes mellitus, arterial hypertension and atherosclerosis.

Inside, during meals; the capsules are swallowed whole with plenty of water. At the initial stage of treatment, 1 capsule (300 mg) is prescribed 3 times a day.

The effect usually develops within 2 weeks, after which the treatment is continued at the same dose or reduced to the minimum maintenance dose - 600 mg, or suspended (while the achieved effect persists for at least 4 weeks). The course of treatment is on average 3-4 weeks, the need for a longer treatment is determined individually.

In diabetic retinopathy, 0.9 - 1.8 g / day is prescribed.

One capsule contains:
Active ingredient: Troxerutin 300 mg.
Excipients: lactose monohydrate, magnesium stearate.
Capsule shell: capsule body - quinoline yellow dye (E 104), sunset yellow dye (E110), titanium dioxide (E 171), gelatin; capsule cap - quinoline yellow dye (E 104), sunset yellow dye (E 110), titanium dioxide (E 171), gelatin.

• Hypersensitivity to rutosides or to other components of the drug

• Pregnancy (I trimester)

• Peptic ulcer and duodenal ulcer

• Chronic gastritis in the acute phase

• Children's age up to three years (solid dosage form) f

Caution should be used (long-term use) in renal failure, children aged 3 to 15 years (see section 'Special instructions').

Trade name: TROXEVAZINЃ

International non-proprietary name:

troxerutin

Dosage form:

capsules

Description: hard cylindrical gelatin capsules No. 1, body - yellow, cap - yellow. Capsule contents: yellow to yellow-green powder.

Composition:

One capsule contains:
Active ingredient: Troxerutin 300 mg.
Excipients: lactose monohydrate, magnesium stearate.
Capsule shell: capsule body - quinoline yellow dye (E 104), sunset yellow dye (E110), titanium dioxide (E 171), gelatin; capsule cap - quinoline yellow dye (E 104), sunset yellow dye (E 110), titanium dioxide (E 171), gelatin.

Pharmacotherapeutic group:

venotonic and venoprotective agent

ATX code —05—ј04

Pharmacological properties.

Angioprotective agent, acts mainly on capillaries and veins.

Reduces the pores between endothelial cells by modifying the fibrous matrix located between endothelial cells.

Inhibits aggregation and increases the degree of erythrocyte deformation; has an anti-inflammatory effect.

In chronic venous insufficiency TroxevasinЃ reduces the severity of edema, pain, seizures, trophic disorders, varicose ulcers. Relieves symptoms associated with hemorrhoids - pain, itching and bleeding.

Due to the beneficial effect of TroxevasinЃ on the permeability and resistance of the capillary walls, it slows down the development of diabetic retinopathy. In addition, its effect on the rheological properties of blood helps to prevent microthrombosis of retinal vessels.

Pharmacokinetics

After oral administration, absorption is about 10-15%. Maximum plasma concentrations are reached on average 2 hours after administration, therapeutic plasma levels remain for 8 hours. It is metabolized in the liver, partially excreted unchanged in the urine (20 -22% of the dose taken) and bile (60 -70% of the dose taken).

Indications for use

Chronic venous insufficiency, postphlebitic syndrome, trophic disorders in varicose veins and trophic ulcers. As an adjunct treatment after vein sclerotherapy and removal of varicose veins. Hemorrhoids (pain, exudation, itching and bleeding).

Venous insufficiency and hemorrhoids during pregnancy, starting from the second trimester.

As an adjunct treatment for retinopathy in patients with diabetes mellitus, arterial hypertension and atherosclerosis.

Contraindications

• Hypersensitivity to rutosides or to other components of the drug

• Pregnancy (I trimester)

• Peptic ulcer and duodenal ulcer

• Chronic gastritis in the acute phase

• Children's age up to three years (solid dosage form) f

Caution should be used (long-term use) in renal failure, children aged 3 to 15 years (see section 'Special instructions').

Application during pregnancy.

TroxevasinЃ should be used during pregnancy (II and III trimesters) and during lactation if the expected benefit to the mother outweighs the possible risk to the fetus and child.

Method of administration and dosage

Inside, during meals; the capsules are swallowed whole with plenty of water. At the initial stage of treatment, 1 capsule (300 mg) is prescribed 3 times a day.

The effect usually develops within 2 weeks, after which the treatment is continued at the same dose or reduced to the minimum maintenance dose - 600 mg, or suspended (while the achieved effect persists for at least 4 weeks). The course of treatment is on average 3-4 weeks, the need for a longer treatment is determined individually.

In diabetic retinopathy, 0.9 - 1.8 g / day is prescribed.

Side effect:

allergic reactions (eg, skin rash), nausea, diarrhea, heartburn, headache, flushing of blood to the face, erosive and ulcerative lesions of the gastrointestinal tract. They quickly disappear after stopping treatment.

Overdose. In case of an overdose, the following symptoms may appear: agitation, nausea, headache, flushing of the face. In case of an overdose, patients need to flush the stomach, take activated charcoal, and, if necessary, begin symptomatic treatment.

Interaction with other medicinal products. The effect is enhanced with the simultaneous administration of ascorbic acid.

Special instructions. If during the period of use of the drug the severity of the symptoms of the disease does not decrease, you should consult your doctor. Taking the drug does not affect motor and mental reactions, does not interfere with driving and working with mechanisms. The experience of using the drug in children under 15 years of age is not enough, which requires caution when using it.

Release form.

Capsules 300 mg. 10 capsules in a PVC / aluminum foil blister, 5 blisters in a cardboard box with instructions for use.

Storage conditions.

In a dry, dark place at a temperature not exceeding 25 ? C.

Keep out of the reach of children!

Shelf life.

5 years.

Do not use after the expiration date.

Conditions of dispensing from pharmacies.

Without recipe.